ArticleOncotarget2017

A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.

Aradhana Awasthi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.